​

ProQR Therapeutics (PRQR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PRQR Stock Forecast

ProQR Therapeutics (PRQR) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $3.63, with a high of $5.00 and a low of $2.00. This represents a 218.42% increase from the last price of $1.14.

High: $5 Avg: $3.63 Low: $2 Last Closed Price: $1.14

PRQR Stock Rating

ProQR Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 1 Strong Buy (11.11%), 7 Buy (77.78%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 7 1 Strong Sell Sell Hold Buy Strong Buy

PRQR Price Target Upside V Benchmarks

TypeNameUpside
StockProQR Therapeutics218.42%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.14$1.14$1.14
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2525---7
Mar, 25251--8
Feb, 25241--7
Jan, 25241--7
Dec, 24231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 14, 2024Keay NakaeLoop Capital Markets$2.50$2.327.76%119.30%
Dec 30, 2022Raymond James Raymond JamesRaymond James$5.00$3.3748.37%338.60%
Dec 22, 2022Jennifer KimCantor Fitzgerald$5.00$2.7085.19%338.60%
Aug 12, 2022Keay NakaeChardan Capital$2.00$0.82143.90%75.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025CitigroupNeutralBuyupgrade
Jan 10, 2025OppenheimerOutperforminitialise
Oct 29, 2024Raymond JamesOutperformStrong Buyupgrade
Apr 18, 2024CitigroupNeutralNeutralhold
Nov 08, 2023Chardan CapitalBuyupgrade
Apr 07, 2023CitigroupNeutralNeutralhold
Mar 30, 2023JMP SecuritiesMarket PerformMarket Outperformupgrade
Dec 23, 2022Raymond JamesOutperformOutperformhold
Dec 22, 2022Cantor FitzgeraldOverweightupgrade
Dec 22, 2022JMP SecuritiesMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.93$-0.96$-0.91$-0.34-----
Avg Forecast$-0.92$-0.90$-0.93$-0.28$-0.33$-0.42$-0.48$-0.53$-0.20
High Forecast$-0.28$-0.28$-0.49$-0.25$-0.24$-0.20$-0.40$-0.42$-0.09
Low Forecast$-1.88$-1.85$-1.55$-0.29$-0.43$-0.54$-0.53$-0.70$-0.37
Surprise %1.09%6.67%-2.15%21.43%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$1.35M$4.04M$6.38M-----
Avg Forecast$9.30M$2.57M$22.14M$17.94M$17.09M$20.06M$13.40M$26.98M$101.91M
High Forecast$16.83M$4.66M$33.32M$46.12M$24.28M$32.87M$21.96M$44.20M$166.97M
Low Forecast$4.35M$1.20M$13.95M$3.64M$12.53M$11.35M$7.58M$15.26M$57.64M
Surprise %--47.37%-81.77%-64.44%-----

Net Income Forecast

$-70M $-57M $-44M $-31M $-18M $-5M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-46.61M$-61.68M$-64.89M$-27.54M-----
Avg Forecast$-41.71M$-45.09M$-57.26M$-28.12M$-23.94M$-31.11M$-37.61M$-45.15M$-16.22M
High Forecast$-33.37M$-36.07M$-45.81M$-22.50M$-19.19M$-16.02M$-32.31M$-33.87M$-7.06M
Low Forecast$-50.06M$-54.11M$-68.72M$-33.74M$-34.89M$-43.36M$-42.92M$-56.42M$-29.67M
Surprise %11.75%36.78%13.32%-2.05%-----

PRQR Forecast FAQ

Is ProQR Therapeutics stock a buy?

ProQR Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ProQR Therapeutics is a favorable investment for most analysts.

What is ProQR Therapeutics's price target?

ProQR Therapeutics's price target, set by 9 Wall Street analysts, averages $3.63 over the next 12 months. The price target range spans from $2 at the low end to $5 at the high end, suggesting a potential 218.42% change from the previous closing price of $1.14.

How does ProQR Therapeutics stock forecast compare to its benchmarks?

ProQR Therapeutics's stock forecast shows a 218.42% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for ProQR Therapeutics over the past three months?

  • April 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is ProQR Therapeutics’s EPS forecast?

ProQR Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.33, marking a -2.94% decrease from the reported $-0.34 in 2023. Estimates for the following years are $-0.42 in 2025, $-0.48 in 2026, $-0.53 in 2027, and $-0.2 in 2028.

What is ProQR Therapeutics’s revenue forecast?

ProQR Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $17.09M, reflecting a 167.82% increase from the reported $6.38M in 2023. The forecast for 2025 is $20.06M, followed by $13.4M for 2026, $26.98M for 2027, and $101.91M for 2028.

What is ProQR Therapeutics’s net income forecast?

ProQR Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-23.941M, representing a -13.08% decrease from the reported $-27.543M in 2023. Projections indicate $-31.111M in 2025, $-37.614M in 2026, $-45.147M in 2027, and $-16.215M in 2028.